Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
In 2023, Endox had revenues of approximately SEK 65 million
The scheme is fully digitized and covers approximately 45% of India's population
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
The site’s GMP Certification has been successfully renewed
The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
Subscribe To Our Newsletter & Stay Updated
